Literature DB >> 15995838

Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy.

Ulrike Mock1, Joachim Bogner, Dietmar Georg, Thomas Auberger, Richard Pötter.   

Abstract

PURPOSE: To assess the potential benefit of proton-beam therapy in comparison to 3-D conformal photon therapy and photon- based intensity-modulated radiotherapy (IMRT) in prostate carcinoma for various stages of disease.
MATERIAL AND METHODS: In five patients a 3-D conformal proton-based (two lateral beams) irradiation technique was compared with 3-D conformal photon-beam radiotherapy (four-field box) and IMRT (seven beams). For each patient different target volumes (CTVs) were defined according to early, intermediate and advanced stages of disease: CTV I consisted of the prostate gland, CTV II encompassed prostate and basis of seminal vesicles, and CTV III the prostate and seminal vesicles. Corresponding planning target volumes PTV I-III were defined by uniformly adding a margin of 5 mm to CTV I-III. Dose-volume histograms (DVHs) were analyzed for the different PTVs and various organs at risk (OARs), i.e., rectal wall, bladder, both femoral heads. In addition, maximum and mean doses were derived for the various structures and irradiated non-target tissue volumes were compared for PTV I-III and the different irradiation techniques. Finally, dose conformity and target dose homogeneity were assessed.
RESULTS: With photon- and proton-based radiotherapy techniques similar dose distributions were determined for PTV I-III: mean and maximum PTV dose values were between 99-104% and 102-107% of the normalized total doses (70 Gy), respectively. Conformity indices varied from 1.4 to 1.5 for the photon techniques, whereas for proton-beam radiotherapy values ranged from 1.1 to 1.4. Both the 3-D conformal and the IMRT photon treatment technique resulted in increased mean doses (approximately 40-80%) for OARs when compared to protons. With both photon techniques non-target tissue volumes were irradiated to higher doses (mean dose difference > or = 70%) compared to proton-beam radiotherapy. Differences occurred mainly at the low and medium dose levels, whereas in high dose levels similar values were obtained. In comparison to conformal 3-D treatments IMRT reduced doses to OARs in the medium dose range, especially for the rectal wall.
CONCLUSION: IMRT enabled dose reductions to OARs in the medium dose range compared to 3-D conformal radiotherapy. A rather simple two-field proton-based treatment technique further reduced doses to OARs compared to photon-beam radiotherapy. The advantageous dose distribution of proton-beam therapy for prostate cancer may result in reduced side effects, which needs to be confirmed in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15995838     DOI: 10.1007/s00066-005-1317-7

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  19 in total

1.  Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.

Authors:  Alexei Trofimov; Paul L Nguyen; John J Coen; Karen P Doppke; Robert J Schneider; Judith A Adams; Thomas R Bortfeld; Anthony L Zietman; Thomas F Delaney; William U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-21       Impact factor: 7.038

2.  Quality assurance evaluation of spot scanning beam proton therapy with an anthropomorphic prostate phantom.

Authors:  K Iqbal; M Gillin; P A Summers; S Dhanesar; K A Gifford; S A Buzdar
Journal:  Br J Radiol       Date:  2013-09-18       Impact factor: 3.039

3.  Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy.

Authors:  Martin Dolezel; Karel Odrazka; Miloslava Vaculikova; Jaroslav Vanasek; Jana Sefrova; Petr Paluska; Milan Zouhar; Jan Jansa; Zuzana Macingova; Lida Jarosova; Milos Brodak; Petr Moravek; Igor Hartmann
Journal:  Strahlenther Onkol       Date:  2010-03-26       Impact factor: 3.621

4.  Technical considerations for noncoplanar proton-beam therapy of patients with tumors proximal to the optic nerve.

Authors:  Masashi Mizumoto; Hidetsugu Nakayama; Mari Tokita; Shinji Sugahara; Haruko Hashii; Takeji Sakae; Koji Tsuboi; Hideyuki Sakurai; Koichi Tokuuye
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

5.  Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity.

Authors:  James B Yu; Pamela R Soulos; Jeph Herrin; Laura D Cramer; Arnold L Potosky; Kenneth B Roberts; Cary P Gross
Journal:  J Natl Cancer Inst       Date:  2012-12-14       Impact factor: 13.506

6.  Proton beam therapy for localized prostate cancer 101: basics, controversies, and facts.

Authors:  Eric S Wisenbaugh; Paul E Andrews; Robert G Ferrigni; Steven E Schild; Sameer R Keole; William W Wong; Sujay A Vora
Journal:  Rev Urol       Date:  2014

7.  IMRT of prostate cancer: a comparison of fluence optimization with sequential segmentation and direct step-and-shoot optimization.

Authors:  Marius Treutwein; Matthias Hipp; Oliver Kölbl; Ludwig Bogner
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

8.  Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial.

Authors:  Gregor Goldner; Valentin Bombosch; Hans Geinitz; Gerd Becker; Stefan Wachter; Stefan Glocker; Frank Zimmermann; Natascha Wachter-Gerstner; Andrea Schrott; Michael Bamberg; Michael Molls; Horst Feldmann; Richard Pötter
Journal:  Strahlenther Onkol       Date:  2009-02-25       Impact factor: 3.621

9.  Searching standard parameters for volumetric modulated arc therapy (VMAT) of prostate cancer.

Authors:  Marius Treutwein; Matthias Hipp; Oliver Koelbl; Barbara Dobler
Journal:  Radiat Oncol       Date:  2012-07-11       Impact factor: 3.481

10.  Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis.

Authors:  Masaharu Hata; Koichi Tokuuye; Shinji Sugahara; Nobuyoshi Fukumitsu; Takayuki Hashimoto; Kayoko Ohnishi; Keiko Nemoto; Kiyoshi Ohara; Yasushi Matsuzaki; Yasuyuki Akine
Journal:  Strahlenther Onkol       Date:  2006-12       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.